Dr. Bendell on FDA Approval of Regorafenib in Liver Cancer | OncLive

Dr. Bendell on FDA Approval of Regorafenib in Liver Cancer

April 27, 2017

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses the FDA approval of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses the FDA approval of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).


x